跳至主要内容
临床试验/ACTRN12618001851257
ACTRN12618001851257已完成1 期

A randomized, double-blind, placebo-controlled study to assess the safety and tolerability of PN-1094A after single and multiple ascending doses of PN-10943A in normal healthy volunteers

Protagonist Pty Ltd.0 个研究点目标入组 97 人开始时间: 2018年11月14日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
97

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 55 Years(—)
性别
Male

入选标准

  • Normal healthy volunteers 18-55 years
  • Good general health,
  • BMI 18-30kg/m2
  • Non-smokers
  • Lab values within normal range. Willing to consume standard meal provided.
  • Ability and willingness to attend visits to the site and provide written informed consent prior to entry into the study.

排除标准

  • History of significant abnormalities or diseases
  • Clinical significant lab or ECG abnormalities
  • Mentally or legally incapacitated
  • History of substance abuse, severe allergic or anaphylactic reactions. Regular Alcohol consumption (>21units per week).
  • Inability to comply with the requirements of the study protocol

研究者

相似试验